파상풍 톡소이드 백신 시장 규모 : 백신 유형별, 연령대별, 최종 용도별, 예측(2024-2032년)

Tetanus Toxoid Vaccine Market size is expected to grow at more than 5.8% CAGR during 2024-2032, driven by rising awareness about the importance of vaccination, expanding immunization programs, and advances in vaccine development and distribution infrastructure.

According to Our World in Data, Tetanus claims approximately 50,000 lives globally each year, with a disproportionate impact on regions characterized by poor sanitation and inadequate vaccination coverage. This increasing number of tetanus-related deaths and disabilities is underscoring the urgent need for widespread immunization efforts. As awareness about the risks associated with tetanus grows, healthcare authorities and governments are intensifying their efforts to expand vaccination programs and improve vaccine accessibility. This heightened focus on tetanus prevention is driving the demand for tetanus toxoid vaccines globally. Moreover, healthcare organizations and advocacy groups are actively promoting vaccination campaigns to educate communities about the importance of immunization in preventing tetanus infections and reducing mortality rates.

The tetanus toxoid vaccine market is classified into vaccine type, age group, end-use and region.

The market size from the tetanus toxoid (TT) vaccine type segment is anticipated to record 5.4% CAGR from 2024 to 2032, due to their widespread use in routine immunization programs and mass vaccination campaigns. TT vaccines are highly effective in preventing tetanus, a potentially fatal disease caused by the bacterium Clostridium tetani. These vaccines also induce immunity by stimulating the body's immune response to produce protective antibodies against the tetanus toxin, thereby conferring long-lasting immunity against the disease.

Tetanus toxoid vaccine market from the adult age group segment is expected to witness 5.3% CAGR through 2032. The growth is driven by increasing awareness among adults about the importance of tetanus vaccination, particularly in high-risk occupational settings, such as healthcare facilities, construction sites, and agricultural fields. Additionally, the aging population and the prevalence of chronic medical conditions that weaken the immune system are underscoring the need for tetanus vaccination among adults to prevent tetanus-related complications and fatalities.

Asia Pacific tetanus toxoid vaccines industry is poised to record 6.3% CAGR up to 2032, fueled by population growth, rapid urbanization, and improving healthcare infrastructure. India, China, and Southeast Asian nations are witnessing significant investments in healthcare and immunization programs, driving the demand for tetanus toxoid vaccines. Furthermore, initiatives, such as the Expanded Program on Immunization (EPI) and the introduction of tetanus toxoid-containing vaccines in national immunization schedules are contributing to the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in vaccines research and development in developed nations
    • 3.2.1.2 Growing cases of tetanus and diphtheria in some countries
    • 3.2.1.3 Increasing government initiatives programs for vaccination
    • 3.2.1.4 Technological advancemen in development of toxoid vaccine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side-effects associated with toxoid vaccine
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutess
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tetanus toxoid (TT)
• 5.3 Diphtheria and tetanus (DT)
• 5.4 Tetanus and diphtheria (Td)
• 5.5 Diphtheria, tetanus, and pertussis (DTaP)
• 5.6 Tetanus, diphtheria, and pertussis (Tdap)
• 5.7 Diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB)
• 5.8 Pentavalent (DTaP-IPV/Hib)
• 5.9 Hexavalent (DTaP-IPV/Hib-HepB)
• 5.10 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pediatric
• 6.3 Adult

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Government organizations
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Bharat Biotech International Limited
• 9.2 Biological E. Limited
• 9.3 Biological Products Institute (BPI) Argentina
• 9.4 Chengdu Institute of Biological Products Co., Ltd.
• 9.5 GlaxoSmithKline
• 9.6 Johnson & Johnson
• 9.7 Merck & Co., Inc.
• 9.8 Mitsubishi Tanabe Pharma Corporation
• 9.9 Panacea Biotec Limited
• 9.10 Pfizer Inc.
• 9.11 Sanofi
• 9.12 Serum Institute of India
• 9.13 Zydus Group